PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20068559-8 2010 CONCLUSIONS: L-carnitine supplementation to diet is useful for reducing TNF-alpha and CRP, and for improving liver function, glucose plasma level, lipid profile, HOMA-IR, and histological manifestations of NASH. Carnitine 13-24 C-reactive protein Homo sapiens 86-89 20863217-9 2010 CONCLUSION: l-Carnitine supplement reduces serum CRP, a marker of systemic inflammation, and plasma fibrinogen, an inflammation-related coagulation factor, in hemodialysis patients. Carnitine 12-23 C-reactive protein Homo sapiens 49-52 15490412-9 2004 Treatment with L-carnitine (20 mg/kg, given intravenously at the end of each dialysis session for 6 mo), significantly decreased serum C-reactive protein (CRP) levels, a proinflammatory cytokine known to inhibit erythropoiesis. Carnitine 15-26 C-reactive protein Homo sapiens 135-153 15827896-0 2005 L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. Carnitine 0-11 C-reactive protein Homo sapiens 41-59 15827896-4 2005 The carnitine-treated group showed a statistically significant decrease in serum C-reactive protein and increase in serum albumin and transferrin, blood hemoglobin, and body mass index. Carnitine 4-13 C-reactive protein Homo sapiens 81-99 15827896-6 2005 These preliminary findings suggest that in MHD patients, L-carnitine therapy may suppress inflammation, particularly among those patients with C-reactive protein > or =3 mg/dL, and may improve protein-energy nutritional status. Carnitine 57-68 C-reactive protein Homo sapiens 143-161 15648000-6 2005 In a pilot study, we provided preliminary evidence that treatment with L-carnitine, 20 mg/kg 3 times weekly at the end of each hemodialysis treatment, was associated with a reduction in serum CRP levels and improvement in anabolic status. Carnitine 71-82 C-reactive protein Homo sapiens 192-195 16861734-6 2006 RESULTS: CRP levels were significantly decreased in carnitine group in contrast to the increase in the control group. Carnitine 52-61 C-reactive protein Homo sapiens 9-12 16861734-8 2006 CONCLUSIONS: There was a significant benefit of L-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients. Carnitine 48-59 C-reactive protein Homo sapiens 63-66 15490412-9 2004 Treatment with L-carnitine (20 mg/kg, given intravenously at the end of each dialysis session for 6 mo), significantly decreased serum C-reactive protein (CRP) levels, a proinflammatory cytokine known to inhibit erythropoiesis. Carnitine 15-26 C-reactive protein Homo sapiens 155-158 28791854-1 2017 BACKGROUND: L-carnitine has been used for several years as an adjuvant therapy in oxidative stress, blood sugar, high-sensitivity C-reactive protein (CRP), anemia, etc. Carnitine 12-23 C-reactive protein Homo sapiens 130-148 34740538-10 2022 RESULTS: Although oral L-carnitine supplementation led to the decreased high-sensitivity C-reactive protein, this change was not significant compared with the placebo. Carnitine 23-34 C-reactive protein Homo sapiens 89-107 33520867-13 2020 Conclusions: L-carnitine supplementation was associated with lowering of CRP, IL-6, TNF-alpha, and MDA, and increasing SOD levels, but did not affect other inflammatory and oxidative stress biomarkers. Carnitine 13-24 C-reactive protein Homo sapiens 73-76 30915521-2 2019 Our aim in this meta-analysis was to determine the effect of L-carnitine on inflammatory mediators including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6). Carnitine 61-72 C-reactive protein Homo sapiens 109-127 30915521-10 2019 The results of the meta-analysis indicated that L-carnitine supplementation was significantly associated with lower levels of CRP in comparison to controls (WMD = -1.23 mg/L; 95% CI: -1.73, -0.72 mg/dL; P < 0.0001). Carnitine 48-59 C-reactive protein Homo sapiens 126-129 35623869-11 2022 l-Carnitine supplementation significantly reduced the levels of CRP (mean change +- SE: -34.9 +- 6.5) and IL-6 (mean change +- SE: -10.64 +- 2.16) compared to the baseline, which is both statistically significant compared with the control group (p < 0.05). Carnitine 0-11 C-reactive protein Homo sapiens 64-67 33596883-0 2021 The effect of L-Carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial. Carnitine 14-25 C-reactive protein Homo sapiens 64-82 33277455-13 2020 CONCLUSION: Significant differences between our groups showed that L-Carnitine could help hemodialysis patients with cardiopulmonary problems to suffer lower rate of inflammation and poor life quality as shown at least in comparison of the two factors including CRP and PETCO2 at rest. Carnitine 67-78 C-reactive protein Homo sapiens 262-265 28982550-12 2018 Inflammation as measured by CRP was also reduced in the carnitine group, compared with the control group. Carnitine 56-65 C-reactive protein Homo sapiens 28-31 28791854-1 2017 BACKGROUND: L-carnitine has been used for several years as an adjuvant therapy in oxidative stress, blood sugar, high-sensitivity C-reactive protein (CRP), anemia, etc. Carnitine 12-23 C-reactive protein Homo sapiens 150-153 28356827-0 2015 Effect of L-carnitine Supplementation on Circulating C-reactive Protein Levels: A Systematic Review and Meta-Analysis. Carnitine 10-21 C-reactive protein Homo sapiens 53-71 28356827-2 2015 There have been a number of clinical reports suggesting that supplementation with L-carnitine can modulate systemic inflammation and lower circulating CRP concentrations, but the results have not been consistent. Carnitine 82-93 C-reactive protein Homo sapiens 151-154 28356827-3 2015 METHODS: A comprehensive literature search in Medline, Scopus and Cochrane Central Register of Controlled Trials was performed in December 2012 to identify clinical trials investigating the impact of oral L-carnitine supplementation on serum/plasma CRP concentration. Carnitine 205-216 C-reactive protein Homo sapiens 249-252 28356827-6 2015 Meta-analysis of included trials revealed a significant reduction of circulating CRP concentrations in subjects under L-carnitine intervention compared to the control treatment. Carnitine 118-129 C-reactive protein Homo sapiens 81-84 28356827-9 2015 CONCLUSIONS: The overall findings of the present meta-analysis support the clinically relevant benefit of L-carnitine supplementation in lowering the circulating levels of CRP. Carnitine 106-117 C-reactive protein Homo sapiens 172-175 25446285-5 2015 All studies in this field, except one, showed that L-carnitine could significantly reduce C-reactive protein and serum amyloid A, as two systemic inflammation markers, in HD patients. Carnitine 51-62 C-reactive protein Homo sapiens 90-108 24368434-5 2014 l-Carnitine significantly decreased serum low-density lipoprotein (LDL) (mean difference: -5.82 mg/dL; 95% CI: -11.61, -0.04 mg/dL) and C-reactive protein (CRP) (-3.65 mg/L; -6.19, -1.12 mg/L). Carnitine 0-11 C-reactive protein Homo sapiens 136-154 24368434-5 2014 l-Carnitine significantly decreased serum low-density lipoprotein (LDL) (mean difference: -5.82 mg/dL; 95% CI: -11.61, -0.04 mg/dL) and C-reactive protein (CRP) (-3.65 mg/L; -6.19, -1.12 mg/L). Carnitine 0-11 C-reactive protein Homo sapiens 156-159 24368434-8 2014 CONCLUSIONS: This meta-analysis failed to confirm the previous findings regarding the effects of l-carnitine on hemoglobin and the erythropoietin dose but showed that l-carnitine significantly decreased serum LDL and CRP. Carnitine 167-178 C-reactive protein Homo sapiens 217-220